Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | IKBKB | O14920 | 9/20 | 0.64 |
| ▸ | CDK2 | P24941 | 5/20 | 0.57 |
| ▸ | CDK1 | P06493 | 1/20 | 0.54 |
| ▸ | CDK4 | P11802 | 1/20 | 0.54 |
| ▸ | CCNE2 | O96020 | 1/20 | 0.47 |
| ▸ | CCNE1 | P24864 | 1/20 | 0.47 |
| ▸ | GSK3B | P49841 | 1/20 | 0.47 |
| ▸ | JAK2 | O60674 | 3/20 | 0.46 |
| ▸ | JAK3 | P52333 | 1/20 | 0.46 |
| ▸ | HDAC1 | Q13547 | 2/20 | 0.46 |
| ▸ | HDAC6 | Q9UBN7 | 2/20 | 0.46 |
| ▸ | NAMPT | P43490 | 1/20 | 0.46 |
| ▸ | CHUK | O15111 | 1/20 | 0.45 |
| ▸ | POLB | P06746 | 1/20 | 0.45 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3520259 | 0.95 | IKBKB (0.65) | IKBKBCDK2CDK1CDK4JAK2 | |
| SCHEMBL3522186 | 0.88 | IKBKB (0.71) | IKBKBCDK2CDK1CDK4CCNE2 | |
| SCHEMBL3519923 | 0.88 | IKBKB (0.55) | IKBKBCDK2CDK4JAK2JAK3 | |
| SCHEMBL3520630 | 0.86 | IKBKB (0.70) | IKBKBCDK2CDK1CDK4CCNE2 | |
| SCHEMBL3520093 | 0.85 | IKBKB (0.72) | IKBKBCDK2CDK1CDK4CCNE2 | |
| SCHEMBL3516112 | 0.84 | IKBKB (0.52) | IKBKBCDK2CDK4JAK2JAK3 | |
| SCHEMBL27680549 | 0.84 | IKBKB (0.49) | IKBKBCDK2CDK4JAK2JAK3 | |
| SCHEMBL3521241 | 0.84 | IKBKB (0.74) | IKBKBCDK2CDK1CDK4CHUK | |
| SCHEMBL3516668 | 0.84 | IKBKB (0.68) | IKBKBCDK2CDK1CDK4CCNE2 | |
| SCHEMBL3521391 | 0.83 | IKBKB (0.58) | IKBKBCDK2CDK1CDK4CHUK |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7799915-B2 | Anilino-pyrimidine analogs | WYETH LLC (US) | 2010-09-21 | — | — | US | claimed |
| US-20060079543-A1 | Anilino-pyrimidine analogs | WYETH (US) | 2006-04-13 | — | — | US | claimed |
| US-7799915-B2 | Anilino-pyrimidine analogs | WYETH LLC (US) | 2010-09-21 | — | — | US | disclosed |
| US-20060079543-A1 | Anilino-pyrimidine analogs | WYETH (US) | 2006-04-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060079543-A1 | Anilino-pyrimidine analogs | DPYD, TYMP, ADORA3 | IKBKB 3246/4885CDK2 11/4885CDK1 43/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.